Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OK, well let me know when I'm wrong. Thanks
You'll be correct until you're not.
Correction, Bunka has never told us whether Altria has said that they are in or out. It's been over 3 years since Altria first agreed to fund research into DehydraTECH and nicotine and they have not put one cent of additional money into funding any further research as allowed in the agreement. So, are they in or out? I think the answer is obvious!
https://ir.lexariabioscience.com/news-events/press-releases/detail/52/altria-group-invests-up-to-12m-in-lexaria-biosciences
Altria has never said they are in or out.
Altria owns part of Lexaria's nicotine subsidiary and although they have lost their exclusivity in the US they still have an agreement with LEXX to pay royalties for any product they sell that uses Dehydratech. They could sign back on to make a new product or use us in an existing one any time they want.
Did not hear anything about the Altria payment, so guess Altria is over and done with Lexx
SOSDD
I don't know how many tuned in. I couldn't be bothered after there was no news in the morning, I got those highlights from someone who did.
I just don't believe him any more, this story about being too busy to do the analysis of HYPER-H21-3 results is pure BS, and now I think he's doing a bait and switch, heh, don't worry about hypertension, look at the nicotine card I just pulled out of the hat again, and don't worry I might have some important news down the road.
Altria has not put any more money into nicotine research re: DehydraTECH, as per their agreement with Lexaria, since their original investigation concluded, so what is Bunka talking about?
'As a result, Altria now has 90 days, or until 11:59 pm on October 8, 2020 to exercise its First Warrant Tranche by way of a further staged payment to Lexaria Nicotine as per the agreements among the parties. This payment would enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECHTM for purposes of oral nicotine delivery.'
You think 5 people tuned in yesterday Shaw? No solid substance besides more testing, similar press, no volume, no movement
A few highlights…
1. Roughly $8.5 M in cash at this time. No plans of any financing and fully funded until mid 2023.
2. Deals with both Altria and BAT are ongoing. Claims there is far more happening with Altria as of now than BAT.
3. Promises at least 6 major news items in the next 6 months; all having the potential to move the stock in a significant way.
The Senate on Thursday unanimously approved a marijuana bill—but not the federal legalization measure that advocates have been eagerly awaiting Senate Majority Leader Chuck Schumer (D-NY) to bring to the floor. Rather, it’s a modest bipartisan piece of legislation that’s simply meant to promote research into marijuana.
The bill—sponsored by Sens. Dianne Feinstein (D-CA), Brian Schatz (D-HI) and Chuck Grassley (R-IA)—is titled the Cannabidiol and Marihuana Research Expansion Act. It cleared the full chamber unanimously, without debate.
It would streamline the application process for researchers who want to study the plant and to encourage the Food and Drug Administration (FDA) to develop cannabis-derived medicines.
It would also clarify that physicians are allowed to discuss the risks and benefits of marijuana with patients and require the U.S. Department of Health and Human Services (HHS) to submit a report on those potential health benefits, as well one on barriers to cannabis research and how to overcome those obstacles.
“Current rules and regulations make it hard for researchers to study how marijuana and marijuana-derived medications can best be used to treat various conditions,” Feinstein said in a press release. “This important legislation will cut the red-tape around the research process, helping get FDA-approved, marijuana-derived medications safely to patients.”
https://www.marijuanamoment.net/u-s-senate-unanimously-approves-marijuana-reform-bill-on-same-day-that-house-schedules-legalization-vote/#:~:text=News%3A%20This%20Senate%20just%20unanimously,encourage%20federal%20research%20into%20CBD.&text=The%20bill's%20other%20original%20cosponsors,Klobuchar%20(D%2DMN).
News: This Senate just unanimously passed a bill to expand scientific and medical research on cannabis and encourage federal research into CBD.
News: This Senate just unanimously passed a bill to expand scientific and medical research on cannabis and encourage federal research into CBD.
— Chuck Schumer (@SenSchumer) March 24, 2022
It use to be exciting, but now it just seems like we are gonna hear more of the same bullshit about research and all the promises of dehydra tech and how much all these industries are worth. Maybe Bumka will announce his retirement and lift everyone's spirits. We can only hope
Greetings,
Please join us again welcoming returning company Lexaria Bioscience, Corp. (NASDAQ: LEXX). The company will be providing an update on Thursday, March 24th at 4:30 pm EST. It's been 8 months since they last presented to our investment community. Please take this opportunity to re-connect with the company.
Please join us
For this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience.
**Must register to receive a webinar link
This Zoom Webinar is an invitation only event and is reserved for accredited investors. The presentation will include an overview of the company's story with recent highlights, followed by a question and answer forum.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide.
Share Price: $3.04
Market Cap: 18.389 M
Avg. Volume: 78,275
Source: Yahoo Finance
LIVE WEBINAR ON March 24th at 4:30 PM EST
Get up, close and personal with Lexaria Bioscience's Chairman and CEO, Christopher Bunka. Learn about their technologies and the outlook of where the company is going.
Please register to Attend Event
Please register to attend. We look forward to meeting you.
Regards,
Raymond Oliver, CEO
Bear Creek Capital
Bringing companies to you up close and personal. Access upper management thru our events while networking with other investors.
If you are looking to gain access to top notch companies working diligently and strategically for their shareholders, these meetings are a great opportunity to access the management team without going thru hurdles such as gate keepers.
You'll never know what does and doesn't happen behind closed doors. Only what does and becomes a news release! Investors have to take forward comments with grains of salt, just like I choose to do with board comments about how Bunka is failing us. For all we know he will pull the proverbial rabbit out of his hat, make a huge tobacco/ pharma deal and make liars out of the majority of us. Hang in there.
Three months to find a scientist to analyze the data? Don't eat that one Elmer, something doesn't smell right! This is almost how he strung us along about nicotine with the tobacco companies, excuses and claiming that he didn't know what the delays were and intimating that their studies were ongoing, when he must of known that they had already walked and at the same time telling us he was in negotiations with even more tobacco companies.
Thanks Shawking. Here's a link to the interview: https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_1c51d72b705e445ea8563b2b6091e0e5.pdf
From Mr. Ted Ohashi.
I spoke to CEO Chris Bunka this week and asked him about SRAX, ChargD+, hypertension, etc. I will publish the interview in my free Let's Toke Business newsletter tomorrow. To get a copy send an email to ltbletter@gmail today.
Yes, threshold is under $1 for 10 days and then I believe, 180 days to get it back above a $1 for 10 days straight and starts over fresh
I believe the threshold is $1
How long can a stock stay below $1 on Nasdaq?
If a company trades for 30 consecutive business days below the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company, advising that it has been afforded a "compliance period" of 180 calendar days to regain compliance with the applicable requirements.
Does anyone know how long the share price can be below $4 and still remain on the NASDAQ?
This will be the next study of DehydraTech. Now you see that they deserve bonus options.
Too bad lexaria can't make my car run more efficiently with less fuel.
options slid in with PR that no one cares about - although another expense...Bunka needs to stfu and do something positive for the company and not just himself.
Incentive.....WTF!!
In other news, Lexaria announces that it has issued an aggregate 36,700 stock options to a total of six employees, consultants and independent directors bearing an exercise price of US$3.39 for a period of five years ending March 8, 2027 (collectively the "Options"). The Options were issued pursuant to the Company's registered Incentive Equity Plan and any common shares issued upon the exercise of the Options will be unrestricted securities.
But only after they have major news and they stay where they are…
I would doubt it…maybe 10 or 20 to 1…
When this goes back to otc is a 1-30 forward split likely?
Bumka must have quit.
Why do you think big pharma "crooked" would want a product that lowers the usage of their product.
Why do you think big pharma "crooked" would want a product that lowers the usage of their product. He has to also overcome crooked back room deals and crooked politicians.
After a while...a long while...and you see evidence that a Company has a superior product, yet the company's stock price goes nowhere but down you have to reach the conclusion that it is management and not the company nor the product.
Additionally, when the market sees that the stock and the company is controlled by one person and that person has the ability to richly reward themselves with both cash compensation and options and warrants, the ability of the stock to appreciate is greatly diminished.
Until proven otherwise, one much conclude that the management of Lexaria is so inept that the stock will slowly sink to zero unless and until management is replaced with professional managers that can realize the full value of the Company's products and process.
Bunko is good at what he does, raising money, trying/spending $$, getting paid handsomely. Either this is $50/$75 or much more in 6 to 9 months or it's history, worthless. Very small chance of the first, but there is a chance.
Bunko annual letter (Just like Warren Buffet - LOL) and PR - the market turns away...reality (I got taken) that was slowly seeping in now floods my investment... tax write off. glta
Stock price and reaction tells you what it is worth right now. Try not to think about any pre split prices, only make you feel worse
Doesn't make any sense, how it can in as little as four minutes after dosing, deliver 74% more sildenafil into the bloodstream and Seven minutes after dosing, achieved an average blood level higher than the generic sildenafil control formulation reached at any point during the study, but the results are not statistically significant.
Doesn't seem superior at all.
"Of note, the reported improvements in delivery rate including the Cmax, Tmax and AUC evidenced in the study did not achieve statistical significance, therefore, supporting further investigation in a larger number of animals."
They should do a campaign like 3M did, "We don't make the product you use, we make it better".
If you have a superior product and nobody is knocking at your door...how superior can it be?
NY Post
In as little as four minutes after dosing, the DehydraTECH formulation delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. Seven minutes after dosing, the DehydraTECH-sildenafil formulation achieved an average blood level higher than the generic sildenafil control formulation reached at any point during the study.
The most well-known sildenafil product for sale in the world today is Viagra®. Sildenafil is moderately bioavailable orally at roughly 40%, but many people find it slow to act. Lexaria's study findings could pave the way for development of faster and better acting sildenafil oral formulations, whether for the Viagra® branded product or its generic pharmaceutical competitors.
Nobody takes Bunka's words seriously, for a reason. Still no explanation of huge compensation with no performance.
Followers
|
220
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
34627
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |